147191-91-1

Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4+ T cells. Priliximab can be used in research of rheumatoid arthritis (RA)[1].

[1] Salvatore A, et, al. Method for prediction of response to immune mediated disease therapeutics. US20130225427.